Our lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and potentially accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate its effects on post-operative ileus and intra-abdominal adhesions and return of gastrointestinal function in subjects undergoing elective bowel resection.